Novo Nordisk (NVO) Stock Today: Worst Year on Record, Fresh Downgrades – and a New 2026 Forecast (11 December 2025)
Novo Nordisk A/S – the Danish maker of Ozempic and Wegovy – is having the kind of year investors usually wake up from, not live through. On 11 December 2025, Novo Nordisk’s U.S.-listed ADRs (ticker NVO) trade around $49 per share, after a bounce of roughly 5–6% in recent sessions. Copenhagen-listed B‑shares sit near 316 DKK, yet they remain close to 50% lower than where they started 2025, putting the stock on track for its worst year on record.MarketBeat+2MarketScreener+2 A new wave of research notes and news out today sharpen the picture: 2026 is now expected to be a year